β-amyloid is a product of APP that is also associated with a decrease in established Alzheimer’s disease [25]; however, it is not clear what plasma APP levels are found in those at risk of developing Alzheimer’s disease and whether an elevation may precede the subsequent decrease in established disease. This evidence concerns the gene APP and Alzheimer disease.